On Jun. 7, 2016, the Texas A&M University System (TAMUS) announced it had entered into a joint development agreement with US-based medical supply store iBio and its subsidiary iBio CMO, in order to develop a collaborative programme in plant-produced pharmaceuticals.

TAMUS includes Texas A&M University AgriLife Research and Texas A&M Institute of Infectious Animal Diseases (IIAD).

The partnership will help strengthen the research and development resources of TAMUS with the commercial therapeutics, as well as vaccine development, along with manufacturing capabilities of iBio.